Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - MA21
MA21 Details
Status: Closed 
Activation Date: 2000DEC04
Closing Date: 2005APR29
Phase: III 

Description: A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel Versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer 

Eligibility: Women with histologically confirmed adenocarcinoma of the breast treated with either total or partial mastectomy; node positive or high risk node negative; T0-T4, N0, N1, or N2, M0; ER status must be known; < 60 years of age; no prior chemotherapy, hormonal therapy, immunotherapy or radiotherapy for breast cancer; adequate blood counts; ECOG < 2; LVEF > institutional lower normal limit; no history of cardiac disease. 

Objective: To compare disease-free survival and overall survival among the three treatment arms. To compare rate of toxicities and quality of life among the three treatment arms. 

Participation: Not Limited 

Lay Description: The purpose of this study is to compare the effects (on you and your breast cancer) of three different combinations of drugs which are commonly used to treat this disease. If you are randomized to Group 1 you will receive three commonly-used chemotherapy drugs called cyclophosphamide, epirubicin and 5 fluorouracil. If you are randomized to Group 2 you will receive three commonly-used chemotherapy drugs called cyclophosphamide, epirubicin and paclitaxel. If you are randomized to Group 3 you will receive three commonly-used chemotherapy drugs called doxorubicin, cyclophosphamide and paclitaxel. This research is being done because currently we do not know which of these three combinations of drugs is better than the others. 

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
BREAST MA21 2104 1202 1488 1488
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
BREAST MA21 2104 27 1084
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
BREAST MA21 2104 0 0 0 0 1 2 0 0